Jingjia reports 2022 H1 revenue increase

Aug.22.2022
Jingjia reports 2022 H1 revenue increase
Jinjia achieved revenue growth despite challenges in the tobacco business, with promising growth in the new tobacco industry.

Jingtian & Gongcheng, a company listed on the Shenzhen Stock Exchange under the symbol 002191.SZ, has released its H1 2022 financial report. The report shows that the company has achieved operating revenue of CNY 2.644 billion, an increase of 8.03% year-on-year. The net profit attributable to shareholders of the listed company amounted to CNY 500 million, a decrease of 1.40% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses amounted to CNY 425 million, a decrease of 11.29% year-on-year. The basic earnings per share is CNY 0.34/share.


During the reporting period, the revenue from cigarette label products decreased by 9.56% compared to the same period last year. The company's cigarette label business experienced some fluctuations due to factors such as intensified regional market competition, decreased bidding prices, fluctuating production raw material costs, and sporadic COVID-19 outbreaks.


During the reporting period, the company achieved a 297.53% increase in revenue from its new tobacco business compared to the same period last year. The company has been actively adapting to new regulations surrounding electronic cigarettes, streamlining and optimizing the mechanism and processes of cooperation among the entities in its new tobacco industry chain. This strategy has effectively leveraged the company's resources, resulting in overall positive growth in areas such as technology research and development, new product development, and customer collaboration. As such, the company has been able to successfully implement high-quality strategies for advancing its new tobacco development plans.


This article contains excerpts or reprints of third-party information. The copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any organization or individual who wishes to reproduce this content should contact the author directly and refrain from direct reproduction.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.
Nov.14 by 2FIRSTS.ai
Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
The payoff is here: BAT’s Vuse has seized a rare regulatory vacuum to reverse its U.S. slide, capitalizing on a crackdown that seemingly compressed the illicit market to 54%. But the victory is fragile. A record $590 million export shock in October signals the gray market is striking back—pitting a fleeting compliance dividend against a massive inventory wall.
BAT
Dec.09
South Korea Again Delays Tobacco Business Act Amendment on Synthetic Nicotine
South Korea Again Delays Tobacco Business Act Amendment on Synthetic Nicotine
South Korea’s amendment to the Tobacco Business Act, which would classify synthetic nicotine vapes and vape liquids as “tobacco” for regulatory and taxation purposes, has been delayed once again. Despite the government stressing its urgency due to youth access and risks of illicit drug mixing, both ruling and opposition parties at the Legislation and Judiciary Committee meeting agreed that the bill requires further discussion.
Nov.13 by 2FIRSTS.ai
UK Retailers Urge Government to Include Age-Verification Tech in Tobacco and Vapes Bill
UK Retailers Urge Government to Include Age-Verification Tech in Tobacco and Vapes Bill
UK convenience retailers have written to several government ministers urging the adoption of age-verification technology in the Tobacco and Vapes Bill. The letter, led by Atul Sodha of Londis, Harefield, and co-signed by 29 other shop owners, calls for a “triple lock” approach combining manufacturer tech, retailer vigilance, and user-level verification to curb youth access.
Nov.28 by 2FIRSTS.ai
PMI Japan Unveils Limited-Edition IQOS ILUMA i “Galaxy Blue,” Priced Around $47
PMI Japan Unveils Limited-Edition IQOS ILUMA i “Galaxy Blue,” Priced Around $47
Philip Morris Japan announced it will release the limited-edition IQOS ILUMA i “Galaxy Blue” across IQOS stores nationwide starting October 29, priced at JPY 6,980 including tax (about USD 47). The new model features a space-themed design, with a members-only promotion to run at the Nagoya IQOS store.
Oct.29 by 2FIRSTS.ai
CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches
CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches
CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.
Nov.04